ArticleBMC cancer2020

Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial.

Relinde I Y Lieverse et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.